Hydroxyurea
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Anemia in Children
Conditions
Sickle Cell Anemia in Children, Sickle Cell Disease
Trial Timeline
Nov 15, 2023 → Sep 1, 2027
NCT ID
NCT05285917About Hydroxyurea
Hydroxyurea is a phase 3 stage product being developed by Novartis for Sickle Cell Anemia in Children. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05285917. Target conditions include Sickle Cell Anemia in Children, Sickle Cell Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05285917 | Phase 3 | Recruiting |
| NCT05853458 | Approved | Terminated |
Competing Products
20 competing products in Sickle Cell Anemia in Children